Avalo Therapeutics to Participate in Upcoming Investor Conferences

Article Stock Quotes (1)

FREE Breaking News Alerts from StreetInsider.com!

StreetInsider.com Top Tickers, 8/26/2026

1. INTU
2. DKS
3. ZM
4. SMTC
5. META

6. SPY
7. NCNO
8. JAZZ
9. NVDA
10. BOX

Get Alerts AVTX Hot Sheet

Price: $20.16 +2.13%

Overall Analyst Rating:
SELL (= Flat)

Join SI Premium – FREE

WAYNE, Pa., June 23, 2025 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a clinical stage biotechnology company focused on the treatment of immune dysregulation, today announced that management will participate in the following investor conferences:

HCW Annual Inflammation & Immunology Virtual Conference
Fireside Chat
June 30, 2025, at 11:00 am ET

BTIG Virtual Biotechnology Conference 2025
1x1s
July 29-30, 2025

Live webcasts and replays, when available, can be found under "News / Events" in the Investors section of the Avalo Therapeutics website at https://ir.avalotx.com. The archived webcast will be available for replay for at least 30 days.

About Avalo Therapeutics

Avalo Therapeutics is a clinical stage biotechnology company focused on the treatment of immune dysregulation. Avalo’s lead asset is AVTX-009, an anti-IL-1β mAb, targeting inflammatory diseases. For more information about Avalo, please visit www.avalotx.com.

About AVTX-009

AVTX-009 is a humanized monoclonal antibody (IgG4) that binds to interleukin-1β (IL-1β) with high affinity and neutralizes its activity. IL-1β is a central driver in the inflammatory process. Overproduction or dysregulation of IL-1β is implicated in many autoimmune and inflammatory diseases. IL-1β is a major, validated target for therapeutic intervention. There is evidence that inhibition of IL-1β could be effective in hidradenitis suppurativa and a variety of inflammatory diseases in dermatology, gastroenterology, and rheumatology.

For media and investor inquiries
Christopher Sullivan, CFO
Avalo Therapeutics, Inc.
[email protected]
410-803-6793

Meru Advisors
Lauren Glaser
[email protected]